Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT00171262
First received: September 12, 2005
Last updated: November 7, 2011
Last verified: November 2011

September 12, 2005
November 7, 2011
August 2004
June 2007   (final data collection date for primary outcome measure)
Change from baseline in serum inflammatory markers after 52 weeks
Not Provided
Complete list of historical versions of study NCT00171262 on ClinicalTrials.gov Archive Site
  • Change from baseline in fibrosis parameters and endothelial function after 52 weeks
  • Adverse events and serious adverse events after 52 weeks
  • Change from baseline in laboratory tests of kidney function after 12 weeks
Not Provided
Not Provided
Not Provided
 
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers

To analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. In addition, tolerability and safety will also be evaluated in a Spanish population.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Dyslipidemia
Drug: Fluvastatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
June 2007
June 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients > 18 years Patients that give their inform consent

Exclusion Criteria:

  • Pregnant women Diabetic patients Treated with statins for the year prior to study inclusion Patients with contraindications listed in fluvastatin prescribing information

Other protocol-defined in and exclusion criteria may apply

Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00171262
CXUO320BES02
Not Provided
Novartis
Novartis
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP